Sign in
CompletedPhase 1

Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome

Key facts

Who runs it
Azitra Inc.
Where
New Haven and Palo Alto, United StatesSee the 2 sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
6 people enrolled
Started
16 Jun 2024
Ended
7 Jul 2026
Type of study
Interventional
Treatments tested
  • ATR12-351
Record updated
29 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Adults ≥18 years of age
  • Confirmed mutation of the serine protease inhibitor of Kazal type 5 (SPINK5) gene
  • Involvement of ≥20% of body surface area with skin changes consistent with Netherton syndrome

Who cannot take part

  • Concurrent involvement in any other clinical study/expanded access program with an investigational drug or device or has participated in a clinical study within 30 days prior to the screening visit
  • History of ultraviolet phototherapy within the planned treatment area 4 weeks prior to baseline
  • Use of biologic therapies, antibiotics, antihistamines, corticosteroids, retinoids, disease-modifying antirheumatic drugs (DMARDs), immunosuppressive agents, phosphodiesterase-4 (PDE4) inhibitors, topical calcineurin inhibitors, or topical Janus kinase (JAK) inhibitors
  • Open wounds or extensive areas of excoriation precluding identification of appropriate application sites in the Investigator's judgment
  • Residing with an immunocompromised person in the same dwelling from the baseline visit through 2 weeks after the treatment period

Where in United States

  • Yale UniversityNew Haven, United States
  • Stanford UniversityPalo Alto, United States

About the trial

What the trial wants to find out

The objectives of this clinical trial are to evaluate the safety and tolerability of topically applied ATR12-351, to understand what the body does to ATR12-351, and to observe treatment benefits of the drug in approximately 12 adult patients with Netherton Syndrome (NS). ATR12-351 will be applied to skin lesions on one side of the body, while the vehicle control will be applied to similar lesion on the other side of the body twice daily for 2 weeks.

The group in the trial

  • Internal controlled armTreatment being tested

    ATR12-351 on left side of body, vehicle on right side of body in one group; vehicle on left side of body, ATR12-351 on right side of body.

    Treatment: ATR12-351

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-Blind, Vehicle-Controlled, First-in-Human Safety, Tolerability and Proof-of-Concept Study of Topical ATR12-351 in Adults With Netherton Syndrome
Record updated
29 July 2026